Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 73.97 Million EUR | 39.78% |
| 2022 | 52.92 Million EUR | 157.3% |
| 2021 | 20.56 Million EUR | 5694.08% |
| 2020 | 355 Thousand EUR | 39.22% |
| 2019 | 255 Thousand EUR | -7.61% |
| 2018 | 276 Thousand EUR | -1.08% |
| 2017 | 279 Thousand EUR | -7.0% |
| 2016 | 300 Thousand EUR | -7.69% |
| 2015 | 325 Thousand EUR | 15.66% |
| 2014 | 281 Thousand EUR | 12.85% |
| 2013 | 249 Thousand EUR | 22.06% |
| 2012 | 204 Thousand EUR | -59.36% |
| 2011 | 502 Thousand EUR | -65.07% |
| 2010 | 1.43 Million EUR | -20.87% |
| 2009 | 1.81 Million EUR | -49.19% |
| 2008 | 3.57 Million EUR | -27.77% |
| 2007 | 4.94 Million EUR | 41.41% |
| 2006 | 3.49 Million EUR | 11.36% |
| 2005 | 3.14 Million EUR | 3106.12% |
| 2004 | 98 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 80.55 Million EUR | 8.89% |
| 2024 Q3 | 65.56 Million EUR | 3.47% |
| 2024 Q2 | 63.36 Million EUR | -21.34% |
| 2023 Q3 | 55.6 Million EUR | 13.79% |
| 2023 Q2 | 48.86 Million EUR | -5.61% |
| 2023 Q1 | 51.77 Million EUR | -2.18% |
| 2023 FY | 73.97 Million EUR | 39.78% |
| 2023 Q4 | 73.97 Million EUR | 33.04% |
| 2022 FY | 52.92 Million EUR | 157.3% |
| 2022 Q1 | 18.39 Million EUR | -10.55% |
| 2022 Q2 | 27 Million EUR | 46.8% |
| 2022 Q4 | 52.92 Million EUR | 107.47% |
| 2022 Q3 | 25.51 Million EUR | -5.55% |
| 2021 Q1 | 1.00 EUR | -100.0% |
| 2021 Q2 | 1.00 EUR | 0.0% |
| 2021 Q4 | 20.56 Million EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2021 FY | 20.56 Million EUR | 5694.08% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 Q3 | - EUR | 0.0% |
| 2020 Q4 | 355 Thousand EUR | 0.0% |
| 2020 FY | 355 Thousand EUR | 39.22% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q4 | 255 Thousand EUR | 25499900.0% |
| 2019 FY | 255 Thousand EUR | -7.61% |
| 2019 Q1 | 1.00 EUR | -100.0% |
| 2019 Q3 | 1.00 EUR | 0.0% |
| 2019 Q2 | - EUR | -100.0% |
| 2018 Q1 | 293 Thousand EUR | 5.02% |
| 2018 Q3 | 280 Thousand EUR | 4.87% |
| 2018 FY | 276 Thousand EUR | -1.08% |
| 2018 Q4 | 276 Thousand EUR | -1.43% |
| 2018 Q2 | 267 Thousand EUR | -8.87% |
| 2017 FY | 279 Thousand EUR | -7.0% |
| 2017 Q4 | 279 Thousand EUR | -8.22% |
| 2017 Q3 | 304 Thousand EUR | -4.4% |
| 2017 Q2 | 318 Thousand EUR | -1.85% |
| 2017 Q1 | 324 Thousand EUR | 8.0% |
| 2016 Q4 | 300 Thousand EUR | -7.98% |
| 2016 FY | 300 Thousand EUR | -7.69% |
| 2016 Q1 | 347 Thousand EUR | 6.77% |
| 2016 Q2 | 322 Thousand EUR | -7.2% |
| 2016 Q3 | 326 Thousand EUR | 1.24% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q2 | 361 Thousand EUR | 0.0% |
| 2015 FY | 325 Thousand EUR | 15.66% |
| 2015 Q4 | 325 Thousand EUR | -5.52% |
| 2015 Q3 | 344 Thousand EUR | -4.71% |
| 2014 Q4 | 281 Thousand EUR | 0.0% |
| 2014 Q2 | 297 Thousand EUR | 0.0% |
| 2014 Q1 | 297 Thousand EUR | 19.28% |
| 2014 FY | 281 Thousand EUR | 12.85% |
| 2013 FY | 249 Thousand EUR | 22.06% |
| 2013 Q3 | 249 Thousand EUR | -7.78% |
| 2013 Q2 | 270 Thousand EUR | 0.0% |
| 2013 Q4 | 249 Thousand EUR | 0.0% |
| 2013 Q1 | 270 Thousand EUR | 32.35% |
| 2012 Q3 | 204 Thousand EUR | -60.54% |
| 2012 Q4 | 204 Thousand EUR | 0.0% |
| 2012 FY | 204 Thousand EUR | -59.36% |
| 2012 Q2 | 517 Thousand EUR | 0.0% |
| 2011 Q2 | 1.06 Million EUR | 0.0% |
| 2011 FY | 502 Thousand EUR | -65.07% |
| 2011 Q4 | 502 Thousand EUR | 0.0% |
| 2010 Q2 | 1.77 Million EUR | 0.0% |
| 2010 FY | 1.43 Million EUR | -20.87% |
| 2010 Q4 | 1.43 Million EUR | 0.0% |
| 2009 Q2 | 4.14 Million EUR | 0.0% |
| 2009 FY | 1.81 Million EUR | -49.19% |
| 2009 Q4 | 1.81 Million EUR | 0.0% |
| 2008 FY | 3.57 Million EUR | -27.77% |
| 2008 Q4 | 3.57 Million EUR | 0.0% |
| 2007 FY | 4.94 Million EUR | 41.41% |
| 2006 FY | 3.49 Million EUR | 11.36% |
| 2005 FY | 3.14 Million EUR | 3106.12% |
| 2004 FY | 98 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -33374.208% |
| ABIVAX Société Anonyme | 1.00 EUR | -7397799900.0% |
| Adocia SA | 272 Thousand EUR | -27097.794% |
| Aelis Farma SA | 53 Thousand EUR | -139481.132% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | -4149.167% |
| genOway Société anonyme | 982.75 Thousand EUR | -7427.644% |
| IntegraGen SA | 311.44 Thousand EUR | -23652.846% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -44838.101% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 6772.764% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -5941.176% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 62174.579% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -81194.505% |
| Valbiotis SA | 1 Million EUR | -7261.002% |
| TheraVet SA | 123.34 Thousand EUR | -59877.947% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -7397799900.0% |
| argenx SE | 281.12 Million EUR | 73.685% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -5771.27% |
| DBV Technologies S.A. | 1.00 USD | -7397799900.0% |
| Genfit S.A. | 4000.00 EUR | -1849350.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -7397799900.0% |
| Innate Pharma S.A. | 1.00 EUR | -7397799900.0% |
| Inventiva S.A. | 417 Thousand EUR | -17640.528% |
| MaaT Pharma SA | 190 Thousand EUR | -38835.789% |
| MedinCell S.A. | -6.71 Million EUR | 1201.847% |
| Nanobiotix S.A. | 200 Thousand EUR | -36889.0% |
| Onward Medical N.V. | 936 Thousand EUR | -7803.632% |
| Oryzon Genomics S.A. | 6029.00 EUR | -1226935.993% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -57695.313% |
| Pharming Group N.V. | 51.38 Million EUR | -43.974% |
| Poxel S.A. | 2.95 Million EUR | -2402.639% |
| GenSight Biologics S.A. | 1.00 EUR | -7397799900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 92.825% |
| Valneva SE | 44.46 Million EUR | -66.37% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -7397799900.0% |